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The aim of this study was to investigate the effects of combining antiangiogenic treatment, epidermal growth factor receptor (EGFR)
targeting and irradiation (RT). We evaluated AZD2171, a highly potent, orally active, vascular endothelial growth factor (VEGF)
signalling inhibitor, gefitinib, an EGFR tyrosine kinase inhibitor and RT. The antitumour efficacy of these treatments, administered alone
and in combination for 2 weeks, was assessed in a VEGF-secreting human head and neck tumour cell line, CAL33 that highly
expresses EGFR, established as xenografts (250mm
3) in nude mice. The median time to reach a tumour volume of 1000mm
3 was
significantly increased for AZD2171 or gefitinib alone compared with the control. Greater inhibition of tumour growth was seen with
the combination of AZD2171þgefitinib compared with either drug alone, and the triple combination compared with either
AZD2171þgefitinib or RT alone. The intensity of endothelial cell staining was slightly reduced by each agent given alone, and
markedly diminished by the double or triple combination. The triple combination almost completely abolished cell proliferation. The
marked RT-induced enhancement in the DNA-repair enzyme ERCC1 expression was totally abolished by the triple combination.
This observation could help to explain the supra-additive antitumour effect produced by this combination and could provide a basis
for future innovative clinical trials.
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Agents that target epidermal growth factor receptor (EGFR)
potentially exert antitumour effects by inhibiting tumour cell
proliferation and survival, as well as reducing the secretion of
proangiogenic growth factors such as vascular endothelial
growth factor (VEGF) and fibroblast growth factor that stimulate
tumour neoangiogenesis (Perrotte et al, 1999; Woodburn,
1999; Ciardiello et al, 2001). It has been reported that EGFR
targeting in tumours may also modulate the migration and
formation of tube-like structures of vascular endothelial cells
(Hirata et al, 2002). More recently, we have shown the presence of
a gefitinib-sensitive functional EGFR pathway in an immortalised
microvascular endothelial cell line of human origin (Bozec et al,
2005). Thus, in addition to direct effects on tumour cells, EGFR-
targeting drugs may also impart an indirect antitumour effect
through antiangiogenic activity. An optimal antiangiogenic
strategy may, therefore, be to combine an EGFR signalling
inhibitor with an agent that selectively targets VEGF-dependent
signalling.
The novel indole-ether quinazoline, AZD2171, is a highly potent
(IC50o 1n M) ATP-competitive inhibitor of recombinant VEGF
receptor-2 (VEGFR-2) tyrosine kinase in vitro (Wedge et al, 2005).
AZD2171 also shows potent activity vs VEGFR-1 (IC50¼5n M) and
VEGFR-3 (IC50p3n M). In human umbilical vein endothelial cells,
AZD2171 inhibited VEGF-stimulated proliferation and VEGFR-2
phosphorylation with IC50 values of 0.4 and 0.5nM, respectively. In
a fibroblast/endothelial cell coculture model of vessel sprouting,
AZD2171 reduced vessel area, length and branching at sub-
nanomolar concentrations. The growth of established human
tumour xenografts in athymic mice was dose-dependently
inhibited by chronic administration of AZD2171. Combining
AZD2171 and gefitinib could potentially provide inhibitory effects
on both endothelial and tumour cells. Recent preclinical studies
suggest that radiotherapy (RT) in combination with antiangio-
genic/vasculature-targeting agents may enhance the therapeutic
ratio of ionising radiation alone (Wachsberger et al, 2005; Cao
et al, 2006; Williams et al, 2007). Thus, the combination of
AZD2171 and gefitinib with RT could also be interesting to
investigate.
Tumour vasculature is a key target in the treatment of solid
tumours, particularly in head and neck cancer (Le and Giaccia,
2003). In the present study, the antitumour activity of AZD2171, in
combination with gefitinib and RT on a number of cellular and
molecular markers in human head and neck tumour xenografts
(CAL33), was investigated.
Revised 16 April 2007; accepted 19 April 2007; published online 26 June
2007
*Correspondence: Dr G Milano, Oncopharmacology Unit, Centre
Antoine-Lacassagne, 33 Avenue de Valombrose, 06189 Nice Cedex 2,
France; E-mail: gerard.milano@nice.fnclcc.fr
British Journal of Cancer (2007) 97, 65–72
& 2007 Cancer Research UK All rights reserved 0007– 0920/07 $30.00
www.bjcancer.com
T
r
a
n
s
l
a
t
i
o
n
a
l
T
h
e
r
a
p
e
u
t
i
c
sMATERIALS AND METHODS
Chemicals
AZD2171 and gefitinib were kindly provided by AstraZeneca,
Macclesfield, Great Britain. Working solutions were prepared as
follows: AZD2171 (375mgl
 1) and gefitinib (7.5gl
 1) were
suspended in 0.9% NaCl, 0.01% Tween 80. For both drugs, the
concentrations were adjusted so as to include the daily dose in
0.2ml of drug suspension. Dulbecco’s modified Eagle’s medium
(DMEM), penicillin, streptomycin and glutamine were purchased
from Whittaker (Verviers, Belgium). Foetal bovine serum (FBS)
was obtained from Dutscher (Brumath, France).
Cell lines
CAL33, a cell line of human head and neck origin, was obtained
from our institution (Centre Antoine-Lacassagne, Nice, France).
This cell line exhibits high EGFR levels (337947624fmolmg
 1
protein high-affinity sites determined by ligand binding assay;
Dassonville et al, 1993) and produces VEGF (C Onesto, CNRS-
UMR6543, personal communication).
The cell line was maintained as monolayer culture in DMEM
supplemented with 10% FBS v/v, 2mM glutamic acid, 50000Ul
 1
penicillin and 80mM streptomycin in a humidified incubator
(Sanyo, Osaka, Japan) at 371C in an atmosphere containing 8%
CO2. Batches of 15 10
6 cells were frozen in FBS supplemented
with 5% dimethyl sulphoxide (v/v) in advance for injection into
mice. Shortly before injection, cells were thawed and suspended in
Ringer lactate.
Mice
Animal experiments were performed in accordance with the
regulations of our institution’s ethics commission and with the
United Kingdom Co-ordinating Committee on Cancer Research
guidelines (Workman et al, 1998). Six-week-old male NMRI nude
mice were purchased from Janvier laboratories (Le Genet sur Isle,
France) and received s.c. inoculation in the right flank of 2 10
6
cells suspended in 100ml of Ringer lactate (n¼10 per treatment
condition). There were five animals per cage with food and water
ad libitum; following tumour cells injection, animal weight and
tumour growth were monitored once a week. Animals were killed
at the end of experiment by cervical disruption; as no signs of
suffering appeared during the experiment (submitted attitude,
weight loss, prostration, vocalisation), no animal has to be killed
before the end of experiment.
Treatment
Mice bearing well-established CAL33 tumours (mean tumour
volume/treatment group B250mm
3) were treated each week with
vehicle alone (controls), AZD2171 (2.5mgkg
 1 every day 0.2ml
p.o.), gefitinib (50mgkg
 1day
 1, 5 days per week, 0.2ml p.o.) and
RT (6Gyday
 1, 3 days per week, 2h after drugs administration)
for 2 weeks. When coadministered, AZD2171 and gefitinib were
given simultaneously. The dose of gefitinib and AZD2171 were
chosen according to preliminary experiments so that each drug
given alone exerts only partial effects on tumour growth.
Radiotherapy was performed with g-rays on tumour only, using
a
60Co unit, the animals being maintained and biologically isolated
from ambient air during RT with a straitjacket made of Saran
wrap film.
The effect of AZD2171 and gefitinib alone or in combination
with RT on tumour growth was evaluated. The effects of the
treatments were calculated, as described previously (Prewett et al,
2002). Evaluation of the effects on tumour growth consisted in
measuring, for all groups, the mean tumour volume at the end of
the observation period for the controls (day 30), when tumours in
this group reached the average volume of 2500mm
3 (maximal
ethically acceptable volume). Fractional tumour volume (FTV) for
each treatment group was calculated as the ratio between the mean
tumour volumes of treated and untreated animals. This was
performed for treatment a (FTVa), for treatment b (FTVb) and for
treatment aþb (FTV aþb). The expected FTV for the aþb
combination was defined as FTVa observed FTVb observed. The
ratio FTVaþb expected/FTVaþb observed was the combination
ratio (CR). If CR41, there are supra-additive effects and if CRo1
infra-additive ones. Strictly additive effects were observed if
CR¼1. Another way to compare treatment effects was to calculate
the time necessary for the tumours to reach a volume of 1000mm
3
(log-rank test).
Tumour analysis
Tumour length and width was measured weekly using a calliper
rule. Tumour volume was calculated as p/6 length width
2 until
animal killing. Animals were killed by spinal cord dislocation and
tumours were subsequently removed surgically. Half of the tumour
was directly frozen in liquid nitrogen for protein analysis and the
other half fixed in paraformaldehyde overnight for analysis of the
microvessel marker, von Willebrand factor (vWF; Dako, polyclonal
antibody ref.: A0082), and the proliferation marker, Ki67 (Dako,
Trappes, France, monoclonal antibody ref.: M7240, MIB-1), using
immunohistochemistry after tumour tissue from the experimental
groups was assembled into microtissue arrays (Simon et al, 2004).
The analysis of vWF concerned both vessel loss and reduction in
vessel area. The analysis of Ki67 took into account both the
intensity of labelling and proportion of labelled cells.
The final score was the result of the examination of three fields
per tumour, and between four and five tumours were investigated
for each treatment group. One hundred  10 magnification images
of regions of high vascular density within the tumour were
analysed in order to quantify tumour angiogenesis (vWF). Staining
intensities were scored as: 1¼slight; 2¼medium; and 3¼strong.
A subgroup (n¼5) was killed on day 23 (the last day of treatment)
and tumours collected, while the remaining animals (n¼5) were
killed in each group, once animals in the group reached a tumour
volume of 2500mm
3. Approximately, these times were reached
on day 30 for control and gefitinib, on day 37 for AZD2171 and
AZD2171þgefitinib, on day 50 for RT, and on day 60 for
AZD2171þgefitinibþRT treatment groups.
Frozen tumours were pulverised in a liquid nitrogen-cooled
Thermovac pulveriser. The resulting powders were homogenised
in 10 volumes of a 10mM Tris-HCl buffer pH 7.4, containing 1mM
EDTA, 0.5mM dithiothreitol, 10mM sodium molybdate, phospha-
tase inhibitor cocktail 2 with a dilution 1/100 and protease
inhibition cocktail 2 with a dilution 1/100, both from Sigma (Saint
Quentin Fallavier, France). The homogenates were centrifuged for
1h at 105000g (þ41C) and the supernatants (cytosols) were used
for protein determination by immunoblotting. Total protein
content was measured using the bicinchoninic acid assay.
Human VEGF secreted by CAL33 xenografted tumours was
determined in tumour cytosol by ELISA using DVE00 (Quantikine,
R&D systems, Lille, France). Epidermal growth factor receptor had
been previously determined by the I
125-EGF-binding method
followed by Scatchard-plot analysis (Dassonville et al, 1993).
The EGFR and VEGFR signalling pathway markers phospho-
ERK1/2, PTEN and phospho-AKT, the apoptosis-related markers
Bax/Bcl2 ratio, the proliferation-related marker p27 and the DNA
repair-related marker ERCC1 were determined by Western blot
(detailed technical conditions are summarised in Table 1).
Two sets of tumours have been analysed with different purposes.
One set (five animals per treatment group) was collected at the end
of treatment period (day 23) in order to compare the effects of the
different treatments on a panel of molecular markers. The other set
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sof tumour-bearing animals was maintained to assess tumour
regrowth after the end of treatment period. Animals were killed
when mean tumour volume of each treatment group reached
2500mm
3. These tumours were used to detect what molecular
parameters could be modified in these tumours escaping to
treatments. The first set of tumours was analysed for vWF
(endothelial cell-specific marker) and Ki67 (proliferative capacity
of tumour cells) by immunohistochemistry, for the EGFR and
VEGFR signalling pathway markers such as phospho-ERK1/2 and
phospho-AKT, for the apoptosis-related markers Bax/Bcl2 ratio,
the proliferation-related markers p21 and p27 and the DNA repair-
related marker ERCC1 (essentially on tumour cells as they largely
outnumber endothelial cells in tumours) by Western blot normal-
ised by Raf as a loading control, and VEGF (human, secreted by
tumour cells only) by ELISA.
The second set of tumours was analysed for phospho-ERK1/2,
phospho-AKT and PTEN expression by Western blot also
normalised by Raf as a loading control.
The bands in the Western blots were quantified using the Chemi
Doc imager from Bio-Rad, Marnes-La-Coquette, France.
Statistical analyses
Comparison of tumour growth between different treatment groups
was performed by Kaplan–Meier-type analysis with the log-rank
statistical test. The effects of treatment on vWF and Ki67 were
evaluated using the non-parametric ANOVA (Kruskal–Wallis
test). The differences between treatment groups for molecular
factors (VEGF, phospho-ERK1/2, PTEN, phospho-AKT, Bax/Bcl2,
ERCC1) were examined using the Mann–Whitney test.
RESULTS
Effects of AZD2171 in combination with gefitinib and
radiation on tumour growth
The effect of the different treatments on tumour growth is shown
in Figure 1. Tumour growth was inhibited by AZD2171 or gefitinib
given alone. These antitumour effects were rapidly established but
disappeared after treatment cessation. In contrast, the antitumour
effects of RT were only seen after 1 week of treatment and persisted
over a longer period. Combination treatment with AZD2171þ
gefitinib produced a greater inhibition of tumour growth than
either treatment alone and led to a growth arrest. Tumour
regrowth occurred after the end of treatment in all groups with
either drugs alone or when combining AZD2171 with gefitinib.
We then considered the AZD2171–gefitinib combination as a
single-drug treatment and examined the effects of its combination
associated with RT. The triple combination (AZD2171þ
gefitinibþRT) produced a greater antitumour effect than either
RT or the AZD2171–gefitinib combination. In comparison to RT
or to the AZD2171–gefitinib combination, the triple combination
prolonged the antitumour effects after treatment discontinued.
Following the treatment period with the triple combination,
growth arrest lasted for 1 week, followed during 3 weeks by a
growth paralleling that of the RT-treated tumours and by a rapid
growth during the last 10 days.
Antitumour effects for AZD2171þgefitinib in combination were
supra-additive (CR¼1.6) as were those for the triple combination
of both drugs administered with RT (CR¼2). These CR values
(41) are consistent with tumour growth inhibition observed with
each regimen.
The median time to reach a tumour volume of 1000mm
3 was
significantly increased for AZD2171 or gefitinib alone compared
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Figure 1 Effects of AZD2171 (2.5mgkg
 1, every day during 2 weeks),
gefitinib (50mgkg
 1, 5 days per week during 2 weeks), RT (6Gy, three
times per week, every 2 days during 2 weeks, 2h after drugs) or a
combination on growth of CAL33 head and neck tumours (mean tumour
volume7s.d., n¼10 per treatment condition until day 24, then n¼5 per
treatment group except for RT where n¼4).
Table 1 Technical conditions of Western blot analyses
Antibody % Acrylamide Dilution Source Supplier
PTEN 12 1/1000 TBS 5% milk Mouse Pharmingen
ERCC1 12 1/500 TBS 5% milk Mouse Neomarkers
Phospho-AKT 12 1/1000 TBS 5% BSA Rabbit Ozyme
P27 12 1/1000 TBS 5% milk Rabbit Pharmingen
Bax 12 1/1000 TBS 5% milk Rabbit Upstate
Bcl2 12 1/1000 TBS 5% milk Rabbit Pharmingen
Phospho-ERK1/2 12 1/5000 TBS 5% milk Mouse Sigma
BSA¼bovine serum albumin; TBS¼tris-buffered saline.
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Figure 2 Respective time delay to reach a tumour volume of 1000mm
3
for the different treatment groups (seven mice for control and gefitinib, six
mice for RT and five mice for all other treatment groups). Of note, two
tumours never reached the 1000mm
3 volume (these tumours were purely
necrotic but still present at the end of the experiment).
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swith the control (P¼0.001). There was also a significant difference
between the combination of AZD2171þgefitinib and either drug
alone (P¼0.006) and between the triple combination and
AZD2171þgefitinib (P¼0.0001) or RT alone (Po0.0001;
Figure 2).
Body weights were measured as surrogate markers of treatment
tolerance with a slight body weight loss in all treatment groups
compared to the control group, thus suggesting that treatments
were well tolerated (Figure 3).
Effects of treatments on molecular parameters
In the first set of tumours (collected at the end of treatment
period), the intensity of vWF staining was slightly reduced by each
agent given alone, and markedly diminished by the double or triple
combination (Po0.0001 for triple association vs control; Figure 4).
The triple combination almost completely abolished prolifera-
tion in tumour cells as shown by the decrease in Ki67 labelling
intensity (Po0.001 for triple association vs control; Figure 5). The
effects on apoptosis-related factors Bax/Bcl2 ratio were incon-
sistent (data not shown). No significant effect on phospho-ERK1/2
and on phospho-AKT was observed with any of the treatment
groups (data not shown).
The marked RT-induced enhancement in ERCC1 expression was
totally abolished by the triple combination (P¼0.04 for the triple
combination vs RT; Figure 6). This result could help to explain the
supra-additive antitumour effect produced by this combination.
Compared with VEGF levels in the control tumours, gefitinib
alone tended to decrease VEGF concentration (P¼0.157), whereas
AZD2171 alone enhanced levels of VEGF in the tumour (P¼0.02
vs control). The combination AZD2171þgefitinib as well as RT
alone had no effect on VEGF levels, whereas the triple combination
was associated with an increase in VEGF (Figure 7).
In addition to measurements of tumour factors at the end of
treatment, there were molecular investigations performed in the
second set of tumours (obtained at the end of follow-up when
tumours had regrown). All tumours were collected at a mean
volume of 2500mm
3. There was a variable diminution of phospho-
ERK1/2 expression as compared to the control for all treatment
conditions (data not shown). All the treatment groups showed an
increase in phospho-AKT expression with the triple association
showing the largest increase (Po0.0001; Figure 8). All treatment
groups showed a marked decrease in PTEN expression, the
phosphorylase, which negatively controls the PI3-Akt pathway
(reaching statistical significance for RT and gefitinibþAZD2171
combination only, P¼0.04 and 0.03, respectively; Figure 9). These
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Figure 3 Profile of body weight vs time among the different treatment
groups (mean weight7s.d., n¼10 per treatment condition until day 24,
n¼5 thereafter).
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Figure 4 Impact of the different treatments on day 24 at the end of the treatment period for the different treatments on vWF (endothelial cell marker),
four microscope fields observed on four tumours (conditions AZD2171, gefitinib, AZD2171–gefitinib), five tumours (conditions RT, AZD2171–gefitinib–
RT), six tumours (control). Magnification  20 for labelling intensity.
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sresults corroborate the effects observed on phospho-AKT. In
addition, all treatments except gefitinib alone showed a marked
decrease in the expression of the cell-cycle regulating protein p27
(P¼0.001; Figure 10). Results with p21 were less consistent (data
not shown).
DISCUSSION
Several preclinical studies have examined the antitumour activity
of inhibitors of EGFR and antiangiogenic agents in combination
and have demonstrated at least additive, if not synergistic, effects
(Ciardiello et al, 2000; Jung et al, 2002; Herbst et al, 2003). These
encouraging data have led to the initiation of clinical studies in
lung cancer, evaluating the combination of erlotinib, an EGFR
tyrosine kinase inhibitor, with bevacizumab, an anti-VEGF anti-
body (Herbst et al, 2005). Previous experimental studies showed
potential beneficial antitumour effects when combining anti-
angiogenic agents with RT (Wachsberger et al, 2005, Nieder
et al, 2006), resulting in at least additive effects on tumour
growth delay despite different radiation schedules, drugs and
doses and combination regimens. Clinical research in this field is
ongoing but additional preclinical studies are needed to further
evaluate drug combinations, including the targeting of EGFR and
VEGF signalling pathways in association with RT. The present
study was designed in a similar way to work published by Raben
et al (2004) who combined gefitinib with vandetanib (a vascular-
targeting agent) and RT. The authors reported that the triple
association induced the greatest effect on tumour growth and
angiogenesis.
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Figure 5 Impact of the different treatments on Ki67 staining (proliferation marker) on day 24 at the end of the treatment period for the different
treatments (four microscope fields observed) on four tumours (conditions AZD2171, gefitinib, AZD2171–gefitinib), five tumours (conditions RT,
AZD2171–gefitinib–RT), six tumours (control). Magnification for labelling intensity:  4 for low and  20 for medium and strong.
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expression7s.d.), three tumours for control and AZD2171–gefitinib–RT and four tumours for all other treatment conditions. A typical example of
Western blot analysis is given. The results were normalised vs Raf taken as a loading control.
Dual inhibition of EGFR and VEGFR pathways
A Bozec et al
69
British Journal of Cancer (2007) 97(1), 65–72 & 2007 Cancer Research UK
T
r
a
n
s
l
a
t
i
o
n
a
l
T
h
e
r
a
p
e
u
t
i
c
sThe present data indicate that the double combination, the
concomitant application of the VEGF signalling inhibitor,
AZD2171, with gefitinib produced more than additive effects with
a CR value of 1.6, and that the triple combination, the concomitant
application of the VEGF signalling inhibitor, AZD2171–gefitinib
association with RT, produced the highest supra-additive anti-
tumour effects with a CR value of 2. Importantly, this triple
combination maintained a longer growth delay in comparison
either to AZD2171–gefitinib double combination or to RT. The
exploration of several tumour markers sustained the antitumour
effects, which were observed. Among them, it was interesting to
note that the antitumour efficacy of the triple combination could
be attributed both to a direct impact on tumour cell proliferation
(Ki67 with a marked decrease in labelling) and on the endothelial
cell network of the tumour (vWF staining). A previous experi-
mental study by our group was performed on an immortalised
microvascular endothelial cell line of human origin (Bozec et al,
2005). This cell line was exposed to a combination, including
gefitinib, with ZM317450 a tyrosine kinase inhibitor against
VEGFR-2 and RT. A marked synergistic interaction for cytotoxic
effect was found with this triple combination only. These data
concur well with the present results showing a decrease of the
number of endothelial cells, as indicated by vWF staining, by
combining AZD2171 with gefitinib and RT compared to untreated
controls and either monotherapy. It was not within the scope of the
present study to examine the effects of the respective associations
between single drugs and RT. The AZD2171–gefitinib combina-
tion was taken as a whole when combined with RT.
Blood plasma levels of VEGF are significantly increased by
VEGFR-2 blockade in mice and were proposed as a surrogate
marker for VEGFR-2 targeted therapy in the clinical situation (Jain
et al, 2006). Sunitinib, a tyrosine kinase inhibitor of VEGFRs, was
shown to increase plasma levels of VEGF in treated patients (Faivre
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set al, 2006a). The present data indicate that AZD2171, a highly
potent VEGFR-2 inhibitor, was able to increase VEGF tumour
expression. The strict tumour origin of the measured VEGF was
based on the fact that the measured VEGF was of human origin.
This observation confirms that changes in VEGF levels under
treatment may be the reflect of modifications occurring in tumour
VEGF expression.
One of the molecular explanations for the supra-additive effects
on tumour growth presently observed may lie in the changes in
tumour expression of the DNA repair protein ERCC1. As expected,
ERCC1 expression was markedly enhanced by RT treatment alone.
When combined with AZD2171 and gefitinib, this RT-dependent
induction of ERCC1 was totally abrogated (Figure 6).
PTEN inactivation and constitutive activation of AKT are
well-defined genetic alterations in the initiation and progression
of tumours (Vivanco and Sawyers, 2002). AKT is a crucial survival
kinase, and interfering with AKT expression is an attractive
strategy to control tumour progression (Goswami et al, 2006).
Interestingly, the present data show that tumour regrowth
was accompanied by marked changes in tumour expression of
PTEN and phospho-AKT. PTEN was found to be significantly
decreased. Conversely, phospho-AKT expression was enhanced
as compared to controls. This was particularly true in tumours
having shown the highest response under treatment (with the
triple combination), AKT is one of the main mTOR-related
messengers (Smolewski, 2006) and the current development of
mTOR inhibitors as anticancer drugs is very promising (Faivre
et al, 2006b). It is suggested that to add mTOR targeting as an
additional sequence of treatment following the presently studied
combination could maintain prolonged antitumour effects over
time. Overall, the present data highlight the interesting antitumour
effects of the triple combination with gefitinib, AZD2171 and
RT. This strategy could serve as a basis for future innovative
clinical trials.
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